然后我的肿瘤医生送我去看淋巴瘤专家，离家2个多小时车程的医学院附属医院，专家建议再做2次HDMTX静注...
SAFETY OF SAME DAY HD-MTX WITH INDUCTION THERAPY FOR DLBCL WITH CONCURRENT CNS DISEASE OR AS PROPHYLAXIS FOR HIGH RISK OF CNS RELAPSEdoi:10.1002/hon.47_2881B. BarlowUniversity of Alabama at Birmingham Hematology/Oncology Birmingham Alabama USAC. D. Bodine...
Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis CD5-positive diffuse large B cell lymphoma (CD5+ DLBCL) is a high-risk lymphoma type. Recently, the PEARL5 (a Phase II trial of DA-EPOCH and Rituximab with......
The standard approach to primary central nervous system lymphomas (PCNSL), that is high-dose methotrexate (HD-MTX)-based chemotherapy followed by whole-bra... AJM Ferreri,R Crocchiolo,A Assanelli,... - 《Leuk Lymphoma》 被引量: 145发表: 2008年 Busulfan and Cyclophosphamide (Bu/Cy) as a...
high‐dose methotrexate (HD‐MTX)primary central nervous system lymphoma (PCNSL)rituximabtemozolomide (TMZ)The purpose of this retrospective study was to compare the efficacy and toxicity of high‐dose methotrexate plus temozolomide (MT regimen) and rituximab plus MT (RMT regimen) in patients with ...
|64|[mtxs001/face_recognition-matlab](https://github.com/mtxs001/face_recognition-matlab)|人脸识别(基于matlab,使用bp网络。)|3|2023-09-15| |65|[ning20320/lbn-zwsb](https://github.com/ning20320/lbn-zwsb)|基于Matlab的指纹识别系统|3|2023-08-05| |66|[BigdogManLuo/powerFlower](https:/...
serves as Science Product Manager for MTX Corporation® in Europe, a company that sells a dietary product with Ashwagandha, has acted as a scientific consultant for MET-Rx in Colombia and is a current scientific affiliate to the "Creatine in Health" scientific advisory ...
|26|[mtxs001/face_recognition-matlab](https://github.com/mtxs001/face_recognition-matlab)|人脸识别(基于matlab,使用bp网络。)|3|0|2023-09-15| |27|[Lusenc/SkyrmionOpticalForce](https://github.com/Lusenc/SkyrmionOpticalForce)|该项目记录笔者科研过程中用到的算法函数,包括矢量场表示、瑞利粒子光学力...
The proportion of nonresponders/responders was also not different when patients were stratified for age (</≥ 20 years), GvHD prophylaxis (CS/CS+MTX), conditioning regimen (TBI yes or no), and phase of the disease (early/advanced; Table 4). The proportion of responders was comparable in ...
-- -- 0:53 App mtxffwkqmhdufiuubafd -- -- 0:58 App zukhexpwgdrpnuicxwls 浏览方式(推荐使用) 哔哩哔哩 你感兴趣的视频都在B站 打开信息网络传播视听节目许可证:0910417 网络文化经营许可证 沪网文【2019】3804-274号 广播电视节目制作经营许可证:(沪)字第01248号 增值电信业务经营许可证 沪B2-...